More companies are incorporating these medications into their treatment programs, but given that this is a new landscape with both proven and emerging uses, companies must measure vital signs, monitor secondary effects, and integrate behavior change into their care plans as they transition patients off these drugs over time
Individual responses, however, vary greatly
Additionally, agonists of GLP-1R have been associated with reduced fasting very low-density lipoprotein (VLDL), which was shown to be weight-independent [20, 21]
however, concomitant metformin therapy was not associated with an increased risk of GI symptoms, or an increased likelihood of GLP-1 RA discontinuation, compared to those who were not taking metformin
It's about understanding the value, the variables, and what you should expect to receive in return for your investment in your health